PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) granted stock options covering 146,000 shares to a newly hired employee under a Nasdaq inducement award provision, a compensation mechanism commonly used by biotechnology companies to recruit talent outside shareholder-approved equity plans.
The clinical-stage cancer drug developer said the award was issued June 8 as an employment inducement under Nasdaq Listing Rule 5635(c)(4), which permits companies to grant equity compensation to new hires outside existing incentive plans if certain disclosure requirements are met.
The options carry an exercise price of $1.71 per share, matching the closing price of Context’s stock on the grant date. The award has a 10-year term.
Under the vesting schedule, one-fourth of the options will vest on the first anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments thereafter. Vesting is contingent on the employee’s continued service with the company.
Inducement grants are frequently used across the biotechnology sector, where competition for scientific, clinical and development personnel remains intense. Nasdaq rules require public disclosure of such awards because they are issued outside shareholder-approved compensation plans.
The grant was not made under Context’s 2021 Long-Term Performance Incentive Plan, according to the company’s disclosure.
Context is developing T-cell engaging bispecific antibodies designed to treat solid tumors, a class of therapies intended to direct immune-system T cells toward cancer cells.
The company’s pipeline includes CTIM-76, a Claudin 6 x CD3 bispecific antibody; CT-95, a Mesothelin x CD3 bispecific antibody; and CT-202, a Nectin-4 x CD3 bispecific antibody.
Context is headquartered in Philadelphia.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.